drugset
drugset / Trial / NCT00165802

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

NCT00165802 ↗

Phase 1 Completed 40 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective therapy or for which no effective therapy exists.

Timeline

Start
2006-05
Primary completion
2007-12
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject E7974 Unknown 0.45 mg/m2 Intravenous

Indications

cancer